Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newsletter Articles
|
Ocugen, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Jun. 18, 2024)Biotech Week, 2024, p.1067NewsRX LLCTexto completo disponível |
|
2 |
Material Type: Newsletter Articles
|
Ocugen, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14Biotech Week, 2024, p.1067NewsRX LLCTexto completo disponível |
|
3 |
Material Type: Newsletter Articles
|
Humacyte, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14Biotech Week, 2024, p.991NewsRX LLCTexto completo disponível |
|
4 |
Material Type: Newsletter Articles
|
Surrozen, Inc. Files SEC Form 424B5, Prospectus : (Apr. 25, 2024)Biotech Week, 2024, p.1091NewsRX LLCTexto completo disponível |
|
5 |
Material Type: Newsletter Articles
|
Alector, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Apr. 25, 2024)Biotech Week, 2024, p.911NewsRX LLCTexto completo disponível |
|
6 |
Material Type: Newsletter Articles
|
Humacyte, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Apr. 29, 2024)Biotech Week, 2024, p.991NewsRX LLCTexto completo disponível |
|
7 |
Material Type: Newsletter Articles
|
Biogen Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Apr. 26, 2024)Biotech Week, 2024, p.933NewsRX LLCTexto completo disponível |
|
8 |
Material Type: Newsletter Articles
|
Alector, Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14Biotech Week, 2024, p.911NewsRX LLCTexto completo disponível |
|
9 |
Material Type: Newsletter Articles
|
Biogen Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14Biotech Week, 2024, p.933NewsRX LLCTexto completo disponível |
|
10 |
Material Type: Newsletter Articles
|
Surrozen, Inc. Files SEC Form 424B5, Prospectus [Rule 424Biotech Week, 2024, p.1091NewsRX LLCTexto completo disponível |